Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News

    Latest News - Page 227

    NCLT allows Shivinder to withdraw plea against elder brother Malvinder Singh

    NCLT allows Shivinder to withdraw plea against elder brother Malvinder Singh

    Medical Dialogues Bureau15 Sept 2018 12:48 PM IST
    New Delhi: Former Fortis Healthcare promoter Shivinder Mohan Singh said that the NCLT allowed former Fortis Healthcare promoter Shivinder Mohan Singh...
    Alembic Pharma gets USFDA nod for Alogliptin and Metformin tablet

    Alembic Pharma gets USFDA nod for Alogliptin and Metformin tablet

    Medical Dialogues Bureau15 Sept 2018 12:47 PM IST
    Alogliptin and Metformin Hydrochloride tablets got tentative market approval from USFDA. It is used as the diabetes drug.New Delhi: Alembic...
    USFDA completes inspection of Nagpur facility, no observation issued: Lupin

    USFDA completes inspection of Nagpur facility, no observation issued: Lupin

    Medical Dialogues Bureau15 Sept 2018 9:41 AM IST
    New Delhi: Drug firm Lupin said the US health regulator has completed an inspection of its Nagpur facility in Maharashtra without any observation. The...
    FDA approves AstraZeneca drug, Lumoxiti for a type of Leukaemia

    FDA approves AstraZeneca drug, Lumoxiti for a type of Leukaemia

    Medical Dialogues Bureau14 Sept 2018 3:15 PM IST
    AstraZeneca got the green signal to treat leukaemia cancer approved by Food Drug Association (FDA). Hairy cell leukaemia is a rare form of blood...
    EU investigating second impurity in Valsartan

    EU investigating second impurity in Valsartan

    Medical Dialogues Bureau14 Sept 2018 3:05 PM IST
    FRANKFURT: Europe's drugs regulator is looking into another potentially cancer-causing substance in a common blood pressure and heart drug produced in...
    Zydus Cadila gets USFDA nod to market Risedronate drug to treat osteoporosis

    Zydus Cadila gets USFDA nod to market Risedronate drug to treat osteoporosis

    Medical Dialogues Bureau14 Sept 2018 2:55 PM IST
    Risedronate tablets are used to treat Paget's disease of bone. Risedronate is in a class of medications called bisphosphonates. Risedronate alters...
    Shivinder to withdraw petition in NCLT against elder brother Malvinder on mothers advice

    Shivinder to withdraw petition in NCLT against elder brother Malvinder on mother's advice

    Medical Dialogues Bureau14 Sept 2018 2:01 PM IST
    New Delhi: Former Fortis Healthcare promoter Shivinder Mohan Singh said he has decided to withdraw his petition in NCLT against elder brother...
    Lupin gets market approval of Atovaquone oral suspension By USFDA

    Lupin gets market approval of Atovaquone oral suspension By USFDA

    Medical Dialogues Bureau13 Sept 2018 2:06 PM IST
    Atovaquone oral suspension used for prevention and treatment of a type of pneumonia.New Delhi: Drug firm Lupin said it has received a approval from...
    Merck KGaA, Pfizer develop Bavencio immuno-drug to alleviate kidney cancer

    Merck KGaA, Pfizer develop Bavencio immuno-drug to alleviate kidney cancer

    Medical Dialogues Bureau13 Sept 2018 2:03 PM IST
    FRANKFURT: Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in...
    Foamix Pharmaceutical acne drug meets Goal in late stage trial

    Foamix Pharmaceutical acne drug meets Goal in late stage trial

    Medical Dialogues Bureau13 Sept 2018 2:02 PM IST
    Foamix Pharmaceutical recently announced that its drug for treating moderate-to-severe acne has met the main goals of its third late-stage study....
    Alcon, Eye Care Unit of Novartis picks Geneva over Texas for new HQ

    Alcon, Eye Care Unit of Novartis picks Geneva over Texas for new HQ

    Medical Dialogues Bureau13 Sept 2018 9:21 AM IST
    ZURICH: The headquarters of Alcon, the eye care unit of Novartis which will be spun off to shareholders in 2019, will move from the division's...
    Sun Pharma: USFDA Scrutinizes Mohali plant in Punjab

    Sun Pharma: USFDA Scrutinizes Mohali plant in Punjab

    Medical Dialogues Bureau12 Sept 2018 1:43 PM IST
    New Delhi: Drug major Sun Pharmaceutical Industries said the US health regulator is conducting an inspection of its Mohali facility in Punjab. The...
    PrevNext

    Popular Stories

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    FDC Ban: Supreme Court Relief to Saridon, Piriton and Dart

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    Ayurvedic Medicines for Blood Sugar, Diet containing Metformin Hydrochloride: Ayurveda Firm Booked

    CDSCO bans OTC sale of topical medications containing hydroquinone from April 1, 2019

    CDSCO bans OTC sale of topical medications containing hydroquinone from April 1, 2019

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

    Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

    Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

    Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

    Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

    Regulation of OTC drugs : CDSCO to soon amend Schedule K of Drugs and Cosmetics Act

    Regulation of OTC drugs : CDSCO to soon amend Schedule K of Drugs and Cosmetics Act

    Only doctor can decide line of treatment of a patient, NOT insurance company: Consumer Court

    Only doctor can decide line of treatment of a patient, NOT insurance company: Consumer Court

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok